These studies indicate that FAPα is a specific marker of lung fibrosis and therefore, the use of FAPα as a biomarker seems to be a promising tool to evaluate fibrogenesis and responses to antifibrotic treatments. Here, FAP is linked to pulmonary fibrosis.